BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB:SNTID)
reported the treatment of the first patient at the Company’s newly
opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This
patient is part of Senesco’s Phase 1b/2a clinical study of its
therapeutic drug candidate, SNS01-T, targeting B-cell cancers.
“We are excited to add SCCA as a clinical site,” stated Leslie J.
Browne, Ph.D., President and Chief Executive Officer of Senesco. “It is
our first site on the west coast and we anticipate its urban location
will help attract patients who meet our patient enrollment needs.”
SCCA is a cancer treatment center that unites physician scientists from
Fred Hutchinson Cancer Research Center, UW Medicine and Seattle
Children’s. The organization strives to provide outstanding care to
cancer patients and to further improve survival rates. By bringing
together the cancer-related patient-care services of the three
institutions, SCCA builds on existing strengths, allows easier
interactions among the cancer experts in each organization and provides
improved access to resources.
“We are very pleased to have added another patient to group 3 of the
SNS01-T study,” stated Alice S. Bexon, M.D., Vice President of Clinical
Development. “At the current dose level of 0.2 mg/kg, which is in the
range where an effect was seen in preclinical cancer models, we are
looking for a stronger effect than was seen at lower doses in groups 1
The study is an open-label, multiple-dose, dose-escalation study, which
is evaluating the safety and tolerability of SNS01-T when administered
by intravenous infusion to approximately 15 relapsed or refractory
multiple myeloma, mantle cell (MCL) or diffuse large B-cell lymphoma
(DLBCL) patients. While the primary objective of this study is to
evaluate safety and tolerability, the effect of SNS01-T on tumor
response and time to relapse or progression will be assessed using
multiple well-established metrics including measurement of monoclonal
protein in multiple myeloma and CT imaging in MCL and DLBC.
About Senesco Technologies, Inc.
Senesco Technologies is a clinical-stage biotech company specializing in
cancer therapeutics. Its proprietary gene regulation technology has
demonstrated the ability to eliminate cancerous cells and protect
healthy cells from premature death. The Company is currently in a phase
1b/2a trial with a product that treats B-cell cancers, which include
multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s B-cell
lymphomas. The technology was developed over the last 15 years through
the discovery that the genetic pathway for cell growth control is common
to both plants and humans.